Published in Oncology (Williston Park) on December 01, 2013
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Patterns of use and short-term complications of breast brachytherapy in the national medicare population from 2008-2009. J Clin Oncol (2012) 3.34
Assessing the impact of a cooperative group trial on breast cancer care in the medicare population. J Clin Oncol (2012) 3.07
Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst (2006) 2.69
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol (2012) 2.61
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer (2014) 2.48
The relationship between clinical benefit and receipt of curative therapy for prostate cancer. Arch Intern Med (2012) 2.48
The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care (2011) 2.38
Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally conservative health care system. Oncology (Williston Park) (2012) 2.29
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy. Oncology (Williston Park) (2010) 2.01
Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.91
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Population based cancer registry analysis of primary tracheal carcinoma. Am J Clin Oncol (2011) 1.71
A retrospective review of 1349 cases of sebaceous carcinoma. Cancer (2009) 1.70
A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. Int J Radiat Oncol Biol Phys (2012) 1.61
The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys (2010) 1.59
Geographical information systems: applications and limitations in oncology research. Oncology (Williston Park) (2011) 1.52
Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care. Med Care (2014) 1.50
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract (2014) 1.47
Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst (2006) 1.44
Management trends in stage I testicular seminoma: Impact of race, insurance status, and treatment facility. Cancer (2014) 1.41
Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment. Urology (2011) 1.40
In regard to "Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series." (Int J Radiat Oncol Biol Phys 2012;83:624-629). Int J Radiat Oncol Biol Phys (2012) 1.37
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood (2010) 1.34
Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. Int J Radiat Oncol Biol Phys (2012) 1.25
Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer (2011) 1.19
Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. Cancer (2014) 1.18
Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am J Clin Oncol (2011) 1.16
The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. J Urol (2011) 1.16
Cancer in Botswana: resources and opportunities. Lancet Oncol (2013) 1.11
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol (2008) 1.11
Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat. Health Aff (Millwood) (2012) 1.09
Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril (2005) 1.08
Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol (2009) 1.08
Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.08
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract (2013) 1.05
The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int (2010) 1.04
Overview of the Surveillance, Epidemiology, and End Results database: evolution, data variables, and quality assurance. Curr Probl Cancer (2012) 1.04
Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys (2009) 1.03
Historical trends in the use of radiation therapy for pediatric cancers: 1973-2008. Int J Radiat Oncol Biol Phys (2012) 1.02
Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer (2014) 1.02
The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications. Int J Radiat Oncol Biol Phys (2012) 1.00
Multidisciplinary care and management selection in prostate cancer. Semin Radiat Oncol (2013) 0.99
Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. Head Neck (2012) 0.96
The cost implications of prostate cancer screening in the Medicare population. Cancer (2013) 0.95
Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol (2011) 0.95
Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw (2013) 0.95
The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer (2014) 0.94
Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys (2010) 0.93
A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer. Clin Cancer Res (2013) 0.93
Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk (2012) 0.92
Out-of-pocket expenses and treatment choice for men with prostate cancer. Urology (2012) 0.92
Long-term response to fractionated radiotherapy of presumed optic nerve sheath meningioma. Br J Ophthalmol (2009) 0.92
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist (2012) 0.92
Limitations and biases of the Surveillance, Epidemiology, and End Results database. Curr Probl Cancer (2012) 0.91
Geographic analysis of the radiation oncology workforce. Int J Radiat Oncol Biol Phys (2011) 0.91
Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys (2012) 0.90
Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer (2011) 0.90
Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non-Small-Cell Lung Cancer. J Thorac Oncol (2015) 0.90
Adjuvant radiotherapy after radical prostatectomy: evidence and analysis. Cancer Treat Rev (2010) 0.89
Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys (2011) 0.89
Variation in receipt of radiation therapy after breast-conserving surgery: assessing the impact of physicians and geographic regions. Med Care (2013) 0.89
Racial disparities in changing to a high-volume urologist among men with localized prostate cancer. Med Care (2011) 0.88
Hospital racial composition and the treatment of localized prostate cancer. Cancer (2011) 0.88
Evaluation of the dosimetric impact of interfractional anatomical variations on prostate proton therapy using daily in-room CT images. Med Phys (2011) 0.87
Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. Expert Rev Anticancer Ther (2011) 0.87
Complications of brain tumors and their treatment. Hematol Oncol Clin North Am (2012) 0.86
National Residency Matching Program (NRMP) results for radiation oncology: 2011 update. Int J Radiat Oncol Biol Phys (2012) 0.86
A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer (2014) 0.86
Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2012) 0.86
Case records of the Massachusetts General Hospital. Case 16-2014. A 46-year-old woman in Botswana with postcoital bleeding. N Engl J Med (2014) 0.85
Comparative effectiveness research in radiation oncology: stereotactic radiosurgery, hypofractionation, and brachytherapy. Semin Radiat Oncol (2014) 0.85
Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys (2012) 0.85
National residency matching program results for radiation oncology: 2012 update. Int J Radiat Oncol Biol Phys (2013) 0.85
Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. Radiother Oncol (2012) 0.84
A new approach to understanding racial disparities in prostate cancer treatment. J Geriatr Oncol (2013) 0.84
Risk of fatal cerebrovascular accidents after external beam radiation therapy for early-stage glottic laryngeal cancer. Head Neck (2013) 0.84
Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer. J Natl Cancer Inst (2014) 0.84
A prognostic index for predicting lymph node metastasis in minor salivary gland cancer. Int J Radiat Oncol Biol Phys (2010) 0.84
A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment. Int J Radiat Oncol Biol Phys (2012) 0.84
Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2011) 0.84
Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU Int (2014) 0.84
Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw (2013) 0.83
Hypofractionated proton therapy for prostate cancer: dose delivery uncertainty due to interfractional motion. Med Phys (2013) 0.83
Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributions. Med Phys (2013) 0.83
Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified? Curr Urol Rep (2013) 0.83
The body of evidence for advanced technology in radiation oncology. J Natl Cancer Inst (2012) 0.83
Testicular doses in image-guided radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys (2011) 0.82
A significant decrease in rectal volume and diameter during prostate IMRT. Radiother Oncol (2011) 0.82
Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys (2013) 0.81